Stonepine Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$232K	Buy	+40,030	New	+$265K	0.2%	69
2025 Q3	–	Sell	-205,100	Closed	-$958K	–	76
2025 Q2	$958K	Buy	205,100 +102,835	+101%	+$471K	0.94%	28
2025 Q1	$561K	Sell	102,265 -80,052	-44%	-$323K	0.55%	37
2024 Q4	$618K	Buy	+182,317	New	+$586K	0.5%	38
2024 Q2	–	Sell	-598,086	Closed	-$1.32M	–	31
2024 Q1	$1.32M	Sell	598,086 -5,338,914	-90%	-$13.8M	1.05%	15
2023 Q4	$14M	Buy	5,937,000 +21,628	+0.4%	+$39.9K	6.03%	6
2023 Q3	$11M	Buy	5,915,372 +415,144	+8%	+$951K	3.66%	8
2023 Q2	$14.4M	Sell	5,500,228 -3,139,977	-36%	-$7.99M	5.2%	7
2023 Q1	$14.1M	Sell	8,640,205 -2,554,984	-23%	-$3.2M	4.72%	6
2022 Q4	$14.9M	Sell	11,195,189 -1,732,979	-13%	-$2.45M	6.26%	6
2022 Q3	$20.2M	Buy	12,928,168 +1,280,751	+11%	+$2.12M	9.07%	4
2022 Q2	$17.9M	Buy	11,647,417 +3,723,361	+47%	+$7.86M	8.35%	3
2022 Q1	$20.3M	Buy	7,924,056 +2,267,683	+40%	+$5.54M	8.41%	3
2021 Q4	$16.6M	Buy	+5,656,373	New	+$12.2M	7.61%	3